AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16484309 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical appearing, taken in the same manner)
Number of subjects: 2019
Study 14509555 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol
Number of subjects: 623
Study 14509555 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium
Number of subjects: 623
Study 14509555 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 623
Study 10696889 — intervention group
Group type: EXPERIMENTAL
Intervention: Transanally introduced stapling technique
Number of subjects: 35
Study 10696889 — intervention group
Group type: COMPARATOR
Intervention: Biofragmentable anastomotic ring
Number of subjects: 35
Study 9236896 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine concentration in colorectal cancer tissue
Number of subjects: 31
Study 9236896 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine concentration
Number of subjects: 31
Study 1546993 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive-videodisc computer lab
Number of subjects: 473
Study 1546993 — intervention group
Group type: COMPARATOR
Intervention: Traditional cadaver-demonstration lab
Number of subjects: 473
Study 2864937 — intervention group
Group type: EXPERIMENTAL
Intervention: etilefrine pivalate (Ep, 20 mg p.o.)
Number of subjects: 24
Study 2864937 — intervention group
Group type: EXPERIMENTAL
Intervention: dihydroergotamine (DHE, 5 mg)
Number of subjects: 24
Study 2864937 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study 29471032 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based telemedicine asthma education intervention
Number of subjects: 393
Study 29471032 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 393
Study 27341683 — intervention group
Group type: EXPERIMENTAL
Intervention: Q-Switched Ruby Laser (QSRL)
Number of subjects: 15
Study 27341683 — intervention group
Group type: COMPARATOR
Intervention: Triple Combination Therapy (TCT)
Number of subjects: 15
Study 25170594 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term preseasonal allergoid immunotherapy
Number of subjects: 31
Study 25170594 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 23787227 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioural therapy (iCBT) program (the Sadness Program)
Number of subjects: 109
Study 23787227 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower distress tolerance scores at baseline
Number of subjects: 109
Study 20595412 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive SAMe (800 mg/twice daily)
Number of subjects: 73
Study 20595412 — intervention group
Group type: COMPARATOR
Intervention: Adjunctive placebo
Number of subjects: 73
Study 18940900 — intervention group
Group type: EXPERIMENTAL
Intervention: plasma total homocysteine (tHcy)
Number of subjects: 923
Study 18940900 — intervention group
Group type: EXPERIMENTAL
Intervention: plasma folate concentrations
Number of subjects: 923
Study 16905077 — intervention group
Group type: EXPERIMENTAL
Intervention: L-O (lidocaine with occlusion of IV flow)
Number of subjects: 350
Study 16905077 — intervention group
Group type: EXPERIMENTAL
Intervention: L-F (lidocaine with free IV flow)
Number of subjects: 350
Study 16905077 — intervention group
Group type: COMPARATOR
Intervention: C-O (control with occlusion of IV flow)
Number of subjects: 350
Study 16905077 — intervention group
Group type: COMPARATOR
Intervention: C-F (control with free IV flow)
Number of subjects: 350
Study 16905077 — intervention group
Group type: EXPERIMENTAL
Intervention: S (sodium bicarbonate with placebo pretreatment)
Number of subjects: 350
Study 16905077 — intervention group
Group type: EXPERIMENTAL
Intervention: L (lidocaine pretreatment)
Number of subjects: 350
Study 16905077 — intervention group
Group type: COMPARATOR
Intervention: P (placebo pretreatment)
Number of subjects: 350
Study 12959741 — intervention group
Group type: EXPERIMENTAL
Intervention: Endogenous digoxin, dolichol, and ubiquinone levels in patients with inflammatory bowel disease
Number of subjects: 0
Study 12959741 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan/tyrosine catabolic patterns in patients with inflammatory bowel disease
Number of subjects: 0
Study 12959741 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholesterol:phospholipid ratio and glycoconjugate level of RBC membrane in patients with inflammatory bowel disease
Number of subjects: 0
Study 12419298 — intervention group
Group type: EXPERIMENTAL
Intervention: Biventricular pacing
Number of subjects: 59
Study 12419298 — intervention group
Group type: COMPARATOR
Intervention: Univentricular pacing
Number of subjects: 59
Study 11720639 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin (120 IU/kg subcutaneously twice daily for more than 6 days)
Number of subjects: 3
Study 11720639 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin
Number of subjects: 3
Study 11720639 — intervention group
Group type: COMPARATOR
Intervention: Control group (Unfractionated heparin)
Number of subjects: 3
Study 8924306 — intervention group
Group type: EXPERIMENTAL
Intervention: Exosurf (2 x 5 mL/kg doses given 12 h apart, first dose at mean age of 18.7 +/- 3.4 h)
Number of subjects: 2
Study 8924306 — intervention group
Group type: COMPARATOR
Intervention: Control group (no surfactant given)
Number of subjects: 2
Study 2201733 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone
Number of subjects: 6
Study 6127028 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol
Number of subjects: 0
Study 6127028 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30785830 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-brain radiotherapy (WBRT) delivered 40 Gy (2 Gy/fraction)
Number of subjects: 140
Study 30785830 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive chemotherapy and autologous stem-cell transplantation (ASCT)
Number of subjects: 140
Study 29021207 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle intervention
Number of subjects: 0
Study 29021207 — intervention group
Group type: COMPARATOR
Intervention: Metformin intervention
Number of subjects: 0
Study 25710565 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (LDA; 81 mg/day)
Number of subjects: 1228
Study 25710565 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1228
Study 24142681 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (G1), without any anti‐arrhythmic drug (AAD)
Number of subjects: 210
Study 24142681 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (G2), with amiodarone or sotalol
Number of subjects: 210
Study 24142681 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3 (G3), with last ineffective AAD
Number of subjects: 210
Study 24142681 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall results after 55 months follow-up
Number of subjects: 210
Study 21956713 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cholecalciferol 150,000 IU every 3 months (n=353)
Number of subjects: 686
Study 21956713 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=333)
Number of subjects: 686
Study 21956713 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cholecalciferol 150,000 IU every 3 months
Number of subjects: 686
Study 21956713 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 686
Study 19638596 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonprescription nicotine replacement therapy (NRT)
Number of subjects: 646
Study 19638596 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarettes
Number of subjects: 646
Study 19638596 — intervention group
Group type: EXPERIMENTAL
Intervention: NRT
Number of subjects: 646
Study 19638596 — intervention group
Group type: EXPERIMENTAL
Intervention: NRT and cigarettes
Number of subjects: 646
Study 17580251 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular tools for diagnosis and treatment of aortic disease
Number of subjects: 0
Study 17580251 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarkers for monitoring
Number of subjects: 0
Study 17580251 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular mechanisms investigation
Number of subjects: 0
Study 15231009 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 kcal/kgLBM/day energy availability treatment
Number of subjects: 29
Study 15231009 — intervention group
Group type: EXPERIMENTAL
Intervention: All restricted energy availability treatments (10, 20, or 30 kcal/kgLBM/day)
Number of subjects: 29
Study 15231009 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy availability treatments (20 and 30 kcal/kgLBM/day)
Number of subjects: 29
Study 15231009 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy availability treatments
Number of subjects: 29
Study 12235954 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter defibrillator (ICD)
Number of subjects: 0
Study 12235954 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual chamber ICDs
Number of subjects: 0
Study 12235954 — intervention group
Group type: EXPERIMENTAL
Intervention: Biventricular ICDs
Number of subjects: 0
Study 12235954 — intervention group
Group type: EXPERIMENTAL
Intervention: ICDs
Number of subjects: 0
Study 10806744 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 micrograms misoprostol
Number of subjects: 48
Study 10806744 — intervention group
Group type: COMPARATOR
Intervention: 50 micrograms misoprostol
Number of subjects: 48
Study 7744561 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 microT (10 mG) electromagnetic fields applied over the right temporal lobe
Number of subjects: 40
Study 7744561 — intervention group
Group type: COMPARATOR
Intervention: 1 microT (10 mG) electromagnetic fields applied over the left temporal lobe
Number of subjects: 40
Study 7744561 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 microT (10 mG) electromagnetic fields applied over both temporal lobes
Number of subjects: 40
Study 7744561 — intervention group
Group type: COMPARATOR
Intervention: Sham-conditions
Number of subjects: 40
Study 2688995 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal salmon calcitonin (200 IU daily) with daily calcium supplement of 500 mg
Number of subjects: 37
Study 2688995 — intervention group
Group type: COMPARATOR
Intervention: Placebo (calcium) group
Number of subjects: 37
Study 2688995 — intervention group
Group type: COMPARATOR
Intervention: Control group (age-matched healthy women without calcium supplementation)
Number of subjects: 37
Study 4574042 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic C.N.S. treatment (craniospinal irradiation plus intrathecal methotrexate)
Number of subjects: 177
Study 4574042 — intervention group
Group type: COMPARATOR
Intervention: No prophylactic C.N.S. treatment
Number of subjects: 177
Study 31958985 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-training inter-rater reliability
Number of subjects: 125
Study 31958985 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-training intra-rater reliability
Number of subjects: 125
Study 31958985 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-training inter-rater reliability
Number of subjects: 125
Study 31958985 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-training intra-rater reliability
Number of subjects: 125
Study 30292415 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS at 2 mA
Number of subjects: 32
Study 30292415 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS at 1 mA
Number of subjects: 32
Study 30292415 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 32
Study 27014012 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS + AE
Number of subjects: 45
Study 24844332 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-10 (100 ng/100 µL)
Number of subjects: 56
Study 24844332 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-10 (5 ng/100 µL)
Number of subjects: 56
Study 24844332 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-10 (25 ng/100 µL)
Number of subjects: 56
Study 24844332 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-10 (250 ng/100 µL)
Number of subjects: 56
Study 24844332 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 23971019 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated care approach (IC)
Number of subjects: 50
Study 23971019 — intervention group
Group type: COMPARATOR
Intervention: Usual care approach (UC)
Number of subjects: 50
Study 20681811 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyapatite (HAP) in dry sol gel form
Number of subjects: 45
Study 20681811 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyapatite (HAP) in liquid precipitate form
Number of subjects: 45
Study 20681811 — intervention group
Group type: COMPARATOR
Intervention: Distilled water (positive control)
Number of subjects: 45
Study 20681811 — intervention group
Group type: COMPARATOR
Intervention: No treatment (negative control)
Number of subjects: 45
Study 19107263 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic probing
Number of subjects: 30
Study 19107263 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual probing by postgraduate students
Number of subjects: 30
Study 19107263 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual probing by associate professors
Number of subjects: 30
Study 19107263 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual probing by undergraduate students
Number of subjects: 30
Study 16884982 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil-based anesthetic technique
Number of subjects: 42
Study 16884982 — intervention group
Group type: COMPARATOR
Intervention: Ketamine and midazolam-based anesthetic technique
Number of subjects: 42
Study 16884982 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 42
Study 16884982 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant use of isoflurane
Number of subjects: 42
Study 14635083 — intervention group
Group type: EXPERIMENTAL
Intervention: Palonosetron 0.25 mg
Number of subjects: 569
Study 14635083 — intervention group
Group type: EXPERIMENTAL
Intervention: Palonosetron 0.75 mg
Number of subjects: 569
Study 14635083 — intervention group
Group type: COMPARATOR
Intervention: Dolasetron 100 mg
Number of subjects: 569
Study 14635083 — intervention group
Group type: EXPERIMENTAL
Intervention: Palonosetron
Number of subjects: 569
Study 10939699 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopexamine (2 microg x kg(‐1) x min(‐1))
Number of subjects: 40
Study 10939699 — intervention group
Group type: COMPARATOR
Intervention: Saline 0.9% (Control)
Number of subjects: 40
Study 10939699 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopexamine
Number of subjects: 40
Study 9316825 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine 0.3 mg/70 kg
Number of subjects: 16
Study 9316825 — intervention group
Group type: COMPARATOR
Intervention: Morphine 10 mg/70 kg
Number of subjects: 16
Study 8399631 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin (20-40 mg)
Number of subjects: 10
Study 3528611 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A (mean dose 7.8 +/- 1.2 mg/kg/day)
Number of subjects: 24
Study 3528611 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A
Number of subjects: 24
Study 3528611 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine
Number of subjects: 24
Study 2498073 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG)
Number of subjects: 24
Study 2498073 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 31301105 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-mm HIGH treatment
Number of subjects: 27
Study 31301105 — intervention group
Group type: COMPARATOR
Intervention: 4-mm LOW treatment
Number of subjects: 27
Study 31301105 — intervention group
Group type: COMPARATOR
Intervention: 6-mm HIGH treatment
Number of subjects: 27
Study 31375879 — intervention group
Group type: EXPERIMENTAL
Intervention: Niraparib 300 mg daily with bevacizumab 15 mg/kg every 21 days
Number of subjects: 12
Study 31375879 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab 15 mg/kg every 21 days
Number of subjects: 12
Study 28466533 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute sugar intake from sugar-sweetened beverages
Number of subjects: 0
Study 28466533 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-ingestion of caffeine with sugar
Number of subjects: 0
Study 27137713 — intervention group
Group type: EXPERIMENTAL
Intervention: Epelsiban (10 to 200 mg single-dose; 10 to 150 mg repeat-dose)
Number of subjects: 48
Study 27137713 — intervention group
Group type: EXPERIMENTAL
Intervention: Epelsiban
Number of subjects: 48
Study 27137713 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK2395448 (metabolite of epelsiban)
Number of subjects: 48
Study 27137713 — intervention group
Group type: EXPERIMENTAL
Intervention: Epelsiban and GSK2395448
Number of subjects: 48
Study 22559997 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple test with two antibiotics and one NSAID or two NSAIDs and one antibiotic performed on the same day (n=22)
Number of subjects: 42
Study 22559997 — intervention group
Group type: COMPARATOR
Intervention: Control group with drugs taken on three separate days (n=20)
Number of subjects: 42
Study 21654249 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrolyzed strongly acidic aqueous solution
Number of subjects: 363
Study 21654249 — intervention group
Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 363
Study 19386683 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg daily for 5 days
Number of subjects: 40
Study 19386683 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 19386683 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Number of subjects: 40
Study 19386683 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin and Placebo
Number of subjects: 40
Study 19386683 — intervention group
Group type: EXPERIMENTAL
Intervention: Acquisition of a new PPM during follow-up
Number of subjects: 40
Study 16317024 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebellar damage
Number of subjects: 15
Study 12220769 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaxseed (40 g/day)
Number of subjects: 25
Study 12220769 — intervention group
Group type: COMPARATOR
Intervention: Hormone replacement therapy (0.625 mg conjugated equine estrogens alone or combined with 100 mg micronized progesterone)
Number of subjects: 25
Study 10629707 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy of the breast alone or zones of regional metastasizing (57 patients) with or without adjuvant chemotherapy or hormone therapy (tamoxifen)
Number of subjects: 254
Study 10629707 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients with tumor size not exceeding 1 cm)
Number of subjects: 254
Study 8552892 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug therapy for polymyositis
Number of subjects: 0
Study 8552892 — intervention group
Group type: EXPERIMENTAL
Intervention: Delta-method approach
Number of subjects: 0
Study 8552892 — intervention group
Group type: EXPERIMENTAL
Intervention: Different transforms for setting confidence limits
Number of subjects: 0
Study 1674014 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 5 mg daily for 4 weeks
Number of subjects: 8
Study 1674014 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 7028258 — intervention group
Group type: EXPERIMENTAL
Intervention: CYT plus bleomycin plus cisplatin (SQ)
Number of subjects: 415
Study 7028258 — intervention group
Group type: EXPERIMENTAL
Intervention: ADR plus 5‐FU plus cisplatin (AD and LC)
Number of subjects: 415
Study 7028258 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin (SQ)
Number of subjects: 415
Study 7028258 — intervention group
Group type: EXPERIMENTAL
Intervention: Responders to any regimen
Number of subjects: 415
Study 7028258 — intervention group
Group type: COMPARATOR
Intervention: CYT plus CCNU (SQ, AD, and LC)
Number of subjects: 415
Study 7028258 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate plus doxorubicin plus CYT plus CCNU (MAC) (SQ and AD)
Number of subjects: 415
Study 7028258 — intervention group
Group type: COMPARATOR
Intervention: Mitolactol plus ADR (AD and LC)
Number of subjects: 415
Study 31211782 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal 25(OH)D
Number of subjects: 5223
Study 31211782 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal calcium
Number of subjects: 5223
Study 31211782 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium (RCTs)
Number of subjects: 5223
Study 31211782 — intervention group
Group type: EXPERIMENTAL
Intervention: 25(OH)D (RCTs)
Number of subjects: 5223
Study 28841903 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle fasciotomy
Number of subjects: 0
Study 28841903 — intervention group
Group type: COMPARATOR
Intervention: Limited fasciectomy
Number of subjects: 0
Study 25162948 — intervention group
Group type: EXPERIMENTAL
Intervention: Gauze suction (GSUC)
Number of subjects: 104
Study 25162948 — intervention group
Group type: COMPARATOR
Intervention: Vacuum-assisted closure (VAC)
Number of subjects: 104
Study 23953384 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischaemic preconditioning (three cycles of 5 min ischaemia and 5 min reperfusion in the left upper arm after induction of anaesthesia)
Number of subjects: 329
Study 23953384 — intervention group
Group type: COMPARATOR
Intervention: Control (no ischaemic preconditioning)
Number of subjects: 329
Study 23953384 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischaemic preconditioning
Number of subjects: 329
Study 20581697 — intervention group
Group type: EXPERIMENTAL
Intervention: Sling exercise training (SET) group (n = 14)
Number of subjects: 24
Study 20581697 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON, n = 10)
Number of subjects: 24
Study 18437013 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracoscopic procedure and pleurodesis with dextrose solution (group B)
Number of subjects: 141
Study 18437013 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracoscopic procedure and pleurodesis with talc-dextrose mixed solution (group C)
Number of subjects: 141
Study 18437013 — intervention group
Group type: COMPARATOR
Intervention: Thoracoscopic procedure only (group A)
Number of subjects: 141
Study 16482238 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day triple therapy (esomeprazole 20 mg, clarithromycin 500 mg, amoxycillin 1 g for 7 days)
Number of subjects: 213